ArriVent Biopharma, Inc.

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backe

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

After a brief lull, the trend for biotech companies going public before they have generated clinical data looks well and truly back. South San Francisco-based Septerna has just outlined its plans to r